Treatment of Chikungunya Virus Disease in the Chronic Phase
The chronic phase of Chikungunya virus disease presents a distinct clinical challenge, requiring a targeted management approach that goes beyond acute-phase care. Clinical decision-making in this phase is guided by phase-specific objectives and a structured analgesic strategy.
Clinical Scenario
This protocol applies to patients in the chronic phase of Chikungunya virus disease. Clinical management of Chikungunya is based on the phase of the disease, and the chronic phase demands its own evidence-based framework.
Treatment Objectives
The key goals in this phase are to limit potential joint damage, decrease the functional and psychological impact of ongoing symptoms, and improve the patient's overall quality of life.
Approach (Partial Overview)
Management of mild symptoms involves analgesic therapy following an established stepwise ladder — beginning with one agent before escalating to others. The complete regimen, including the full sequence, agent selection criteria, and symptom-score thresholds, is available in the structured protocol.
References
- The clinical management of Chikungunya is based on the phase of the disease.
- The treatment objectives in this phase of illness are to limit the potential joint damage, decrease the functional and psychological impact and improve the quality of life.
- Paracetamol followed by NSAIDs according to the analgesic ladder is used for mild symptoms (Visual Analog Scale score 1-3).